Stocks and Finance

Protalix BioTherapeutics

Protalix BioTherapeutics 2/16/2012

13:01 : Protalix BioTherapeutics ([[PLX]] -10.6%) says its sale of 4.5M shares ... - Protalix BioTherapeutics (PLX -10.6%) says its sale of 4.5M shares priced at $5.25 per share, a 14% discount to yesterday's close. Post your comment!
Source : seekingalpha-com

Protalix BioTherapeutics 1/9/2012

09:10 : Shares of Protalix BioTherapeutics (PLX) gain 5.3% premarket after investor - Shares of Protalix BioTherapeutics (PLX) gain 5.3% premarket after investors take a hard look at biotech drug names following the BMY-Inhibitex deal. The firm is aiming to develop a groundbreaking Gaucher disease treatment. ...
Source : seekingalpha-com

Protalix BioTherapeutics 12/6/2011

09:27 : Protalix BioTherapeutics (PLX) -18.4% premarket as it says the FDA extends - Protalix BioTherapeutics (PLX) -18.4% premarket as it says the FDA extends the goal date for approving its new drug application for taliglucerase alfa, a treatment for Gaucher disease, to May 1 from Feb. 1. Protalix ...
Source : seekingalpha-com

Protalix BioTherapeutics 8/17/2011

10:19 : Protalix BioTherapeutics ([[PLX]] +6%) pops after the FDA accepts a resubm - Protalix BioTherapeutics (PLX +6%) pops after the FDA accepts a resubmitted new drug application for its experimental drug taliglucerase alfa, which is being developed to treat a rare genetic ailment called Gaucher's ...
Source : seekingalpha-com
actualidad Protalix BioTherapeutics -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts